29th July, 2026: Chennai, India — Nichi-In Centre for Regenerative Medicine (NCRM), an unit of MediNippon Healthcare Pvt. Ltd.,an Indo-Japan healthcare company, the R & D collaborator of GN Corporation Co. Ltd., Japan, will present nearly two decades of collaborative translational research at an international webinar to be hosted by SMC Laboratories, Inc., Japan, on 21 August 2026. The webinar will highlight the outcome of a unique translational research ecosystem established through sustained collaboration among scientists, clinicians, academic institutions and industry partners in India, Japan and other countries, yielding novel solutions in healthcare based on original technologies from Japan.

The webinar will showcase three representative innovations arising from this approach:

Innovation 1: Providing a solution to Physicians from a basic science technology: BEES-HAUS & BHES-HAUS

Urologists looking forward to a long term disease recurrence-free solution for male urethral stricture when approached us, we found a synergy with our tissue engineering platform using Festigel scaffold and developed BEES-HAUS (Buccal epithelium Expanded and Encapsulated in Scaffold‐Hybrid Approach to Urethral Stricture) cell therapy. A pilot clinical study was successfully completed. Pre-clinical proof of cell engraftment was also undertaken and the technology was subsequently transferred to Japan. The BEES-HAUS was further simplified as BHES-HAUS (Buccal Epithelium Hashed and Encapsulated in Scaffold – Hybrid Approach to Urethral Stricture), a single sitting procedure incorporating Festigel scaffold, whose encouraging outcome was presented at the American Urology Association (AUA) meeting 2026. BHES-HAUS has a global market potential of 2 billion US dollars.



Innovation 2: Value adding a food supplement to make it a drug-adjuvant for a rare disease

Our global network of physician-scientists upon studying the properties of " target="_blank">two forms of exo-polysaccharide beta glucans approved as food supplements in Japan, whose dosage had been standardized like that of a drug, compared their specific efficacies in phased pre-clinical studies taking the expertise of SMC laboratories and discovered the immune modulating potentials of one of the products which led to the development of a safe and efficacious disease modifying adjuvant for Duchenne Muscular Dystrophy (DMD), a rare and progressive genetic disorder. This product has now received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. FDA.

Innovation 3: Clinical translation of an implant in a suitable rare disease patient: STAR-MING

For an ultra-rare disease of Parry Romberg Syndrome with hemi-facial atrophy when an oral and maxillofacial surgeon was looking for a bio inert non-immunogenic non-antigenic non-biodegradable filler until the time when the patient have to undergo a final surgical correction procedure after epiphyseal fusion, found a synergy with our STAR-MING implant. The STAR-MING implant can be cut into an size and can be inserted using a very small incision because 3D printed materials may require large incisions, which on face might be disfiguring and hence they opted for STAR-MING. A clinical study was undertaken with more than nine years follow up proving the safety and efficacy of the STAR-MING implant. The STAR-MING as a facial aesthetic filler and future as a breast implant has a global market potential of Three billion US Dollars.

About NCRM & MediNippon Healthcare Pvt. Ltd.

NCRM, unit of MediNippon Healthcare Pvt. Ltd. is an Indo-Japan healthcare organization established with the objective of developing solutions in healthcare based on innovative Japanese technologies, products and scientific expertise through inter-disciplinary research among a global network of physician-scientists with expertise in broad range of domains from agriculture to Zoology, including biomaterials and tissue engineering. Since 2002, this mission has yielded many path-breaking solutions in healthcare, including some reaching clinical stage.

About GN Corporation Co. Ltd.

GN Corporation Co. Ltd., Japan, headquartered in Kofu, Yamanashi, has built an interdisciplinary translational research network bringing together physicians, scientists, engineers, academic institutions and industry partners across countries. For nearly two decades, GN Corporation's approach has focused on identifying promising basic-science technologies, unique biomaterials and healthcare innovations particularly those developed or available in Japan and matching them with unmet clinical needs.

About SMC Laboratories, Inc.

SMC Laboratories, Inc., Japan, is a specialized preclinical contract research organization with expertise in disease models and preclinical study design. SMC supports pharmaceutical and biotechnology research by providing preclinical platforms that facilitate translational drug development.

Webinar Details

Date: 21 August 2026
Time: 8:00–9:00 AM JST

United States: 20 August 2026
4:00–5:00 PM PDT | 7:00–8:00 PM EDT

Format: Online | Free of Charge

Registration link: Watch the webinar

Co-hosted by: SMC Laboratories, Inc., Japan & GN Corporation Co. Ltd.

Media & Collaboration Enquiries

NCRM, A Unit of MediNippon Healthcare Pvt. Ltd.
Chennai, India
mail@medinippon.jp

GN Corporation Co. Ltd.
Kofu, Yamanashi, Japan info@gncorporation.com

SMC Laboratories, Inc.
Tokyo, Japan Email: sato@smclab.co.jp

Image: Left: Dr. Suryaprakash, presenting the encouraging outcome of BHES-HAUS for male urethral stricture in AUA 2026 (American Urological Association Annual meeting 2026). Right: STAR-MING implant as facial filler and breast implant is estimated to have a global market potential of 3.0 Billion USD as per market research reports.